9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors (NCT06926998) | Clinical Trial Compass
Not Yet RecruitingPhase 1/2
9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors
China260 participantsStarted 2025-04-15
Plain-language summary
To evaluate the safety, tolerability, and preliminary efficacy of 9MW2821 in combination with other anti-tumor agents in patients with advanced gynecological malignancies.
Who can participate
Age range
18 Years – 75 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Competent to comprehend, sign, and date an independent ethics committee/institutional review board/research ethics board (IEC/IRB/REB) approved informed consent form.
. Female subjects aged 18 to 75 years (including 18 and 75 years).
. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
. Histopathological diagnosed of advanced gynecological tumors.
. Subjects must submit tumor tissues for test.
. Life expectancy of ≥ 12 weeks.
. Subjects must have measurable disease according to RECIST (version 1.1).
. Adequate organ functions.
Exclusion criteria
. History of another malignancy within 3 years before the first dose of study drug.
. Patients with ongoing clinically significant toxicities related to prior treatment.
. Presence of Grade ≥ 2 peripheral neuropathy.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
. Exclusion of prior diseases and prior treatments as specified in the protocol.
. Comorbidities: a. Hemoglobin A1C ≥ 8%; b. Ocular diseases or symptoms present prior to the first dose of study medication; c. Severe respiratory diseases; d. Clinically significant cardiovascular or cerebrovascular diseases within 6 months prior to the first dose of study medication; e. Active autoimmune diseases within 2 years prior to the first dose of study medication, or a history of autoimmune diseases with potential for recurrence; f. Active infections; g. Severe arterial or venous thromboembolic events.
. Clinically significant bleeding symptoms or a clear bleeding tendency within 3 months prior to the first dose of medication.
. Subjects with central nervous system (CNS) metastases and/or carcinomatous meningitis.
. Pleural, peritoneal, or pericardial effusion with clinical symptoms or requiring repeated drainage procedures.